Idioma:

Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies

ANTA, Lourdes ; LLIBRE, Josep M ; POVEDA, Eva ; BLANCO, Jose L ; ALVAREZ, Marta ; PEREZ-ELIAS, María J ; AGUILERA, Antonio ; CABALLERO, Estrella ; SORIANO, Vicente ; MENDOZA, Carmen De

AIDS (London), 2013-01, Vol.27 (1), p.81-85 [Periódico revisado por pares]

Hagerstown, MD: Lippincott Williams & Wilkins

Texto completo disponível

Citações Citado por

Enviar para

Título:
Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies
Autor: ANTA, Lourdes ; LLIBRE, Josep M ; POVEDA, Eva ; BLANCO, Jose L ; ALVAREZ, Marta ; PEREZ-ELIAS, María J ; AGUILERA, Antonio ; CABALLERO, Estrella ; SORIANO, Vicente ; MENDOZA, Carmen De
Assuntos: Adult ; AIDS/HIV ; Algorithms ; Anti-HIV Agents - pharmacology ; Anti-HIV Agents - therapeutic use ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Biological and medical sciences ; Cross-resistance ; Drug Resistance, Viral - genetics ; Efavirenz ; Female ; Genotype ; Genotypes ; HIV Reverse Transcriptase - antagonists & inhibitors ; HIV Seropositivity - drug therapy ; HIV Seropositivity - genetics ; HIV-1 - drug effects ; HIV-1 - genetics ; Human immunodeficiency virus ; Human viral diseases ; Humans ; Immunodeficiencies ; Immunodeficiencies. Immunoglobulinopathies ; Immunopathology ; Infectious diseases ; Male ; Medical sciences ; Mutation ; Nevirapine ; Nitriles - pharmacology ; Nitriles - therapeutic use ; non-nucleoside reverse transcriptase inhibitors ; Nucleosides - therapeutic use ; Pharmacology. Drug treatments ; Pyrimidines - pharmacology ; Pyrimidines - therapeutic use ; Reverse Transcriptase Inhibitors - pharmacology ; Reverse Transcriptase Inhibitors - therapeutic use ; Rilpivirine ; RNA, Viral - drug effects ; RNA-directed DNA polymerase ; Spain - epidemiology ; Treatment Failure ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids ; Viral Load - drug effects
É parte de: AIDS (London), 2013-01, Vol.27 (1), p.81-85
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
Descrição: Rilpivirine (RPV) is the latest approved nonnucleoside reverse transcriptase inhibitor (NNRTI). It displays in-vitro activity extending over other NNRTI-resistant HIV strains. There is scarce information about the rate of RPV resistance-associated mutations (RAMs) in patients failing other NNRTIs. RPV RAMs were examined in plasma samples collected from HIV patients that had recently failed NNRTI-based regimens at 22 clinics in Spain. Resistance tests from a total of 1064 patients failing efavirenz (EFV) (54.5%), nevirapine (NVP) (40%) or etravirine (ETR) (5.5%) were examined. The prevalence of RPV RAMs was K101E (9.1%), K101P (1.4%), E138A (3.9%), E138G (0.3%), E138K (0.3%), E138Q (0.8%), V179L (0.2%), Y181C (21.8%), Y181I (0.5%), Y181V (0.2%), H221Y (8.3%), F227C (0.1%) and M230L (1.5%). K101E/M184I was seen in 1%. E138K/M184I were absent. Mutations L100I and V108I were significantly more frequent in patients failing EFV than NVP (7.9 vs. 0.2 and 12.2 vs. 7.3%, respectively). Conversely, Y181C, Y181I, V106A, H221Y and F227L were more prevalent following NVP than EFV failures. Using the Spanish resistance interpretation algorithm, 206 genotypes (19.3%) from patients failing NNRTI (NVP 52%, EFV 40.8% and ETR 7.8%) were considered as RPV resistant. In patients with ETR failure, cross-resistance to RPV was seen in 27.6%, mainly as result of Y181C (81.3%), V179I (43.8%), V90I (31.3%) and V108I (18.8%). RPV resistance is overall recognized in nearly 20% of patients failing other NNRTIs. It is more common following ETR (27.6%) or NVP (25%) failures than EFV (14.5%). E138 mutants are rarely seen in this context.
Editor: Hagerstown, MD: Lippincott Williams & Wilkins
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies

ANTA, Lourdes ; LLIBRE, Josep M ; POVEDA, Eva ; BLANCO, Jose L ; ALVAREZ, Marta ; PEREZ-ELIAS, María J ; AGUILERA, Antonio ; CABALLERO, Estrella ; SORIANO, Vicente ; MENDOZA, Carmen De

Hagerstown, MD: Lippincott Williams & Wilkins

Buscando em bases de dados remotas. Favor aguardar.